Alerta

BIOLOGICAL TARGET AND ITS USE IN TREATING OR PREVENTING NEURODEGENERATIVE DISEASES

Resumen de: WO2026148492A1

Provided are a biological target and associated therapeutic strategies for treating or preventing neurodegenerative diseases characterized by pathological α-synuclein (α-syn) fibril transmission.

ISOLATING A MEMBRANE PROTEIN USING A NATIVE CELL MEMBRANE NANOPARTICLE

Resumen de: WO2026151828A1

Provided are methods of isolating or extracting human mitochondrial tryptophan-rich sensory protein (HsTSPOl). The methods include contacting the H.sTSPOl with an effective amount of at least one Native Cell Membrane Nanoparticle (NCMN) polymer and recovering the TSPO. Compositions containing TPSO encapsulated in a particle formed by the NCNM polymer are also provided. A protoporphyrin derivative compound, methods of producing bilindigin or derivatives thereof, and methods of screening compounds that modulate TSPO activity are also provided.

BILIARY TRACT CANCER TREATMENT WITH ANTI-CLAUDIN 18.2 ADC

Resumen de: US20260199509A1

Provided herein is a method of treating biliary tract cancers in humans. The method uses an antibody-drug conjugate (ADC) comprising an antibody (or antigen-binding fragment thereof) which specifically binds claudin 18.2 (CLDN18.2). The ADC is used for treatment of biliary tract cancers which express CLDN18.2.

METHOD OF MANUFACTURING BIOSENSOR FOR DETECTING BIOMARKER OF ALZHEIMER'S DISEASE AND BIOSENSOR MANUFACTURED THEREFROM

Resumen de: US20260202374A1

The present disclosure provides a method of manufacturing a biosensor for detecting a biomarker of Alzheimer's disease, comprising steps of depositing an aluminum oxide film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing electrical contacts Cr/Au on the Al2O3/Si substrate by a thermal evaporator to form a source, a drain and a planar gate on the Al2O3/Si substrate; providing a bilayer graphene on the Al2O3/Si substrate by thermal annealing under a vacuum environment; providing a bilayer graphene to a low-damage plasma treatment (LDPT) with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite on the Al2O3/Si substrate; and immobilizing an antibody on a surface of the GO/G layered composite through a reaction between amine groups of the antibody and carboxyl groups of GO of the GO/G layered composites, wherein the antibody is specific for p-tau217 protein.

PROTEIN ANTIGEN COMBINATION FOR ALZHEIMER'S DISEASE DETECTION AND USE

Resumen de: AU2024418168A1

A protein antigen for Alzheimer's disease detection comprises at least any two of DOC2A, LGALS1, KDM4D, and ADARB1 proteins at the same time, can be used for early detection or diagnosis of Alzheimer's disease, and is suitable for risk assessment and prediction of before the onset of Alzheimer's disease; moreover, the protein antigen can distinguish Alzheimer's disease from other types of dementia, and can be further prepared into a related reagent or kit according to requirements.

TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) PRODUCED BY HUMAN NEURAL OR GLIAL CELLS

Resumen de: EP4775992A2

Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).

SYSTEM AND METHOD FOR PROTEIN CORONA SENSOR ARRAY FOR EARLY DETECTION OF DISEASES

Resumen de: EP4775995A2

0001 The present disclosure provides sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME

Resumen de: EP4775994A2

The present disclosure relates to the identification and use of biomarkers (e.g., analytes, analyte profiles, or markers (e.g., gene expression and/or protein expression profiles)) with clinical relevance to cytokine release syndrome (CRS).

Genetically modified normal pressure hydrocephalus animal model and method for producing the same

Resumen de: KR20260111211A

본 발명은 포크헤드 박스 단백질 J1(Forkhead box protein J1) 돌연변이 및 CR6-상호작용 인자 1(CR6-interacting factor 1, Crif1) 결손 돌연변이를 포함하는 Foxj1-creERT2Crif1-/- 유전자 변형 정상압 수두증 동물 모델에 관한 것으로, 구체적으로는 뇌압의 증가없이 뇌실 확장의 특징을 가져 고령화에 의한 정상압 수두증의 연구 및 치료제 스크리닝에 이용할 수 있다.

IgG 항체를 분석하기 위한 Fc 수용체 기반 검정

Resumen de: WO2025106313A1

The present disclosure is related to compositions and methods for analyzing IgG antibody activity or activation of Fcγ receptors by certain antibodies. Also disclosed are transformed cells expressing human Fcγ receptors useful in methods for analyzing IgG antibody bioactivity.

- Biomarker composition for diagnosing sarcopenia related aging or Alzheimer's disease comprising BACE1 beta-amyloid beta-amyloid oligomer soluble amyloid precursor protein-beta or combination thereof and use thereof

Resumen de: WO2026151160A1

The present invention relates to a biomarker composition for diagnosing sarcopenia caused by aging or Alzheimer's dementia, comprising BACE1, β-amyloid, β-amyloid oligomer, water-soluble amyloid precursor protein-β, or a combination thereof, and to a use thereof. Specifically, the present invention relates to a composition for diagnosing sarcopenia caused by aging or Alzheimer's dementia, comprising, as an active ingredient, an agent for measuring the level of at least one protein or mRNA selected from the group consisting of BACE1, β-amyloid, β-amyloid oligomer, and water-soluble amyloid precursor protein-β, to a kit for diagnosing sarcopenia using the composition, and to a method for providing information for diagnosing sarcopenia.

시그마-1 수용체 요법에서 대리 바이오마커를 사용하는 방법

Nº publicación: KR20260111668A 15/07/2026

Solicitante:

ANAVEX LIFE SCIENCES CORP [US]
\uC544\uB098\uBCA1\uC2A4 \uB77C\uC774\uD504 \uC0AC\uC774\uC5B8\uC2DC\uC2A4 \uCF54\uD504.

Resumen de: WO2025117826A1

The present disclosure provides precision medicine or personalized therapy of using a Sigma-1 receptor agonist in treating neurological disease or disorder. The precision medicine or personalized therapy involves patient selection through differentially expressed genes or affected biological pathways related to the Sigma-1 receptor agonist therapy. Also provided are kits for practicing the methods.